Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | ACR | P10323 | 1/20 | 0.49 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27991105 | 0.98 | PARP10 (0.58) | PARP10KMT2AMAPTTDP1ALDH1A1 | |
| SCHEMBL27623147 | 0.98 | PARP10 (0.58) | PARP10KMT2AMAPTTDP1ALDH1A1 | |
| SCHEMBL483229 | 0.92 | PARP10 (0.55) | PARP10KMT2AMAPTTDP1ALDH1A1 | |
| Water SCHEMBL27261959 | 0.87 | PARP10 (0.68) | PARP10KMT2AMAPTTDP1ALDH1A1 | |
| SCHEMBL725405 | 0.85 | PARP10 (0.77) | PARP10KMT2AMAPTTDP1ALDH1A1 | |
| SCHEMBL31888 | 0.85 | PARP10 (0.70) | PARP10KMT2AMAPTTDP1ALDH1A1 | |
| SCHEMBL1870544 | 0.85 | PARP10 (0.70) | PARP10KMT2AMAPTTDP1ALDH1A1 | |
| SCHEMBL10636639 | 0.83 | PARP10 (0.68) | PARP10KMT2AMAPTTDP1ALDH1A1 | |
| SCHEMBL61632 | 0.83 | PARP10 (0.68) | PARP10KMT2AMAPTTDP1ALDH1A1 | |
| SCHEMBL9663679 | 0.83 | PARP10 (0.81) | PARP10KMT2AMAPTTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1769 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024146922-A1 | C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | DOMPE' FARMACEUTICI SPA (IT) | 2024-07-11 | — | — | WO | claimed |
| EP-4397306-A1 | C5AR1 INHIBITORS FOR USE IN THE TREATMENT OF OCULAR MUCOUS MEMBRANE PEMPHIGOID AND/OR ORAL MUCOUS MEMBRANE PEMPHIGOID | Dompe' Farmaceutici S.P.A. (IT) | 2024-07-10 | — | — | EP | claimed |
| US-20240180888-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | DOMPE' FARMACEUTICI SPA (IT) | 2024-06-06 | — | — | US | claimed |
| EP-4308114-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | Dompe' Farmaceutici SpA (IT) | 2024-01-24 | — | — | EP | claimed |
| CN-117337176-A | C5AR1 inhibitors for treating hypersensitivity to taxanes | 东佩制药股份公司 | 2024-01-02 | — | — | CN | claimed |
| CN-116096563-A | Composition for electronic device encapsulation, method for forming electronic device encapsulation film, and electronic device encapsulation film | 柯尼卡美能达株式会社 | 2023-05-09 | — | — | CN | claimed |
| CN-115806675-A | Hydrogen bond organic framework material constructed based on carboxyl porphyrin ligand and preparation method and application thereof | 中国科学院福建物质结构研究所 | 2023-03-17 | — | — | CN | claimed |
| CN-107155328-B | Composition for display sealing material and display device containing the same | 三星SDI株式会社 | 2022-05-31 | — | — | CN | claimed |
| US-20200397725-A1 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | DOMPE' FARMACEUTICI S.P.A. (IT) | 2020-12-24 | — | — | US | claimed |
| EP-3723744-A2 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | Dompé farmaceutici S.p.A. (IT) | 2020-10-21 | — | — | EP | claimed |
| EP-0321504-B1 | CHIRAL ARYLOXY PROPIONIC ACID ESTERS AND THEIR USE AS DOPING AGENT IN LIQUID CRYSTAL PHASES | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-01-08 | — | — | EP | claimed |
| US-4985172-A | CONVERT SMECTIIC INTO FERROELECTRIC LIQUID CRYSTALS | HOECHST AG (DE) | 1991-01-15 | — | — | US | claimed |
| EP-0077209-B1 | NITROGEN-CONTAINING PROSTACYCLIN ANALOGUES AND COMPOSITIONS CONTAINING THEM | THE UPJOHN COMPANY (US) | 1987-01-07 | — | — | EP | claimed |
| EP-0009362-B1 | HETEROCYCLIC DERIVATIVES OF GUANIDINE, THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS COMPRISING THEM | McNeilab, Inc. (US) | 1984-06-27 | — | — | EP | claimed |
| US-4391980-A | FOR INVERSION OF CONFIGURATION OF OPTICALLY ACTIVE COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1983-07-05 | — | — | US | claimed |
| EP-0011372-B1 | 1-ACYLOXYPHENYL-1,2-DIPHENYLALKENE DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE AND A PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-02-09 | — | — | EP | claimed |
| EP-0004727-B1 | BLOOD PLATELET AGGREGATION INHIBITORY PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND PROCESSES FOR THEIR MANUFACTURE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-08-12 | — | — | EP | claimed |
| US-4275201-A | Aryl substituted diketones | STERLING DRUG INC. (US) | 1981-06-23 | — | — | US | claimed |
| EP-0004727-A2 | Blood platelet aggregation inhibitory pyridine derivatives, pharmaceutical compositions thereof, and processes for their manufacture | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-10-17 | — | — | EP | claimed |
| US-3988326-A | Process for N-acylation of 7 amino cephem compounds | MEIJI SEIKA KAISHA, LTD. (JA) | 1976-10-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180888-A1 | C5AR1 INHIBITORS FOR TREATING HYPERSENSITIVITY REACTIONS TO TAXANES | C5AR1, C5AR2, C3AR1 | PARP10 180/4885KMT2A 3353/4885MAPT 3127/4885 |
| US-20200397725-A1 | C5AR INHIBITORS FOR USE IN THE TREATMENT OF CHEMOTHERAPY-INDUCED IATROGENIC PAIN | C5AR2, C5AR1, C3AR1 | PARP10 269/4885KMT2A 4050/4885MAPT 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.